Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Seminars in Immunopathology
Erschienen in: Seminars in Immunopathology 5/2019

07.10.2019 | Review

Osteoclastic microRNAs and their translational potential in skeletal diseases

verfasst von: Kazuki Inoue, Shinichi Nakano, Baohong Zhao

Erschienen in: Seminars in Immunopathology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Skeleton undergoes constant remodeling process to maintain healthy bone mass. However, in pathological conditions, bone remodeling is deregulated, resulting in unbalanced bone resorption and formation. Abnormal osteoclast formation and activation play a key role in osteolysis, such as in rheumatoid arthritis and osteoporosis. As potential therapeutic targets or biomarkers, miRNAs have gained rapidly growing research and clinical attention. miRNA-based therapeutics is recently entering a new era for disease treatment. Such progress is emerging in treatment of skeletal diseases. In this review, we discuss miRNA biogenesis, advances in the strategies for miRNA target identification, important miRNAs involved in osteoclastogenesis and disease models, their regulated mechanisms, and translational potential and challenges in bone homeostasis and related diseases.
Literatur
1.
2.
Goldring SR, Purdue PE, Crotti TN, Shen Z, Flannery MR, Binder NB, Ross FP, McHugh KP (2013) Bone remodelling in inflammatory arthritis. Ann Rheum Dis 72(Suppl 2):ii52–ii55PubMedCrossRef
3.
Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development. 132(21):4653–4662PubMedCrossRef
4.
5.
Meydan C, Shenhar-Tsarfaty S, Soreq H (2016) MicroRNA regulators of anxiety and metabolic disorders. Trends Mol Med 22(9):798–812PubMedCrossRef
6.
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116(2):281–297CrossRefPubMed
7.
Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469PubMedCrossRef
8.
He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 5(7):522–531PubMedCrossRef
9.
Olive V, Minella AC, He L (2015) Outside the coding genome, mammalian microRNAs confer structural and functional complexity. Sci Signal 8(368):re2PubMedPubMedCentralCrossRef
10.
Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, Mc Curdy DK, Sharma S, Wong D, Hahn BH, Rehimi H (2013) The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 12(12):1160–1165PubMedCrossRef
11.
Srinivasan S, Selvan ST, Archunan G, Gulyas B, Padmanabhan P (2013) MicroRNAs -the next generation therapeutic targets in human diseases. Theranostics. 3(12):930–942PubMedPubMedCentralCrossRef
12.
Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D (2008) Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58(4):1001–1009PubMedCrossRef
13.
Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203–222PubMedCrossRef
14.
Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS (2017) Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids 8:132–143PubMedPubMedCentralCrossRef
15.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368(18):1685–1694PubMedCrossRef
16.
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science. 294(5543):853–858PubMedCrossRef
17.
AJ S, S L, JJ S (2008) al e. MIcrorna expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama. 299:425–436
18.
19.
Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12(11):847–865PubMedPubMedCentralCrossRef
20.
21.
Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R (2004) The microprocessor complex mediates the genesis of microRNAs. Nature. 432(7014):235–240PubMedCrossRef
22.
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S et al (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature. 425(6956):415–419PubMedCrossRef
23.
Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA precursors. Science. 303(5654):95–98PubMedCrossRef
24.
Park JE, Heo I, Tian Y, Simanshu DK, Chang H, Jee D, Patel DJ, Kim VN (2011) Dicer recognizes the 5′ end of RNA for efficient and accurate processing. Nature. 475(7355):201–205PubMedPubMedCentralCrossRef
25.
Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 436(7051):740–744PubMedPubMedCentralCrossRef
26.
Peters L, Meister G (2007) Argonaute proteins: mediators of RNA silencing. Mol Cell 26(5):611–623PubMedCrossRef
27.
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell. 115(7):787–798PubMedCrossRef
28.
29.
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M et al (2005) Combinatorial microRNA target predictions. Nat Genet 37(5):495–500PubMedCrossRef
30.
Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, Filippidis C, Dalamagas T, Hatzigeorgiou AG (2013) DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res 41(Web Server issue):W169–W173PubMedPubMedCentralCrossRef
31.
Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9(2):102–114CrossRefPubMed
32.
Miller CH, Smith SM, Elguindy M, Zhang T, Xiang JZ, Hu X, Ivashkiv LB, Zhao B (2016) RBP-J-regulated miR-182 promotes TNF-alpha-induced osteoclastogenesis. J Immunol 196(12):4977–4986PubMedCrossRef
33.
Maeda Y, Farina NH, Matzelle MM, Fanning PJ, Lian JB, Gravallese EM (2016) Synovium-derived microRNAs regulate bone pathways in rheumatoid arthritis. J Bone Miner Res
34.
Krishnan K, Steptoe AL, Martin HC, Wani S, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Gabrielli B, Vlassov A, Cloonan N, Grimmond SM (2013) MicroRNA-182-5p targets a network of genes involved in DNA repair. RNA. 19(2):230–242PubMedPubMedCentralCrossRef
35.
Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K, Song JJ, Kingston RE, Borowsky M, Lee JT (2010) Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 40(6):939–953PubMedPubMedCentralCrossRef
36.
Licatalosi DD, Mele A, Fak JJ, Ule J, Kayikci M, Chi SW, Clark TA, Schweitzer AC, Blume JE, Wang X, Darnell JC, Darnell RB (2008) HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature. 456(7221):464–469PubMedPubMedCentralCrossRef
37.
Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M Jr, Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 141(1):129–141PubMedPubMedCentralCrossRef
38.
Helwak A, Kudla G, Dudnakova T, Tollervey D (2013) Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell. 153(3):654–665PubMedPubMedCentralCrossRef
39.
Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466(7308):835–840PubMedPubMedCentralCrossRef
40.
41.
Sugatani T, Hruska KA (2013) Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis. J Cell Biochem 114:1217–1222PubMedPubMedCentralCrossRef
42.
Mizoguchi F, Murakami Y, Saito T, Miyasaka N, Kohsaka H (2013) miR-31 controls osteoclast formation and bone resorption by targeting RhoA. Arthritis Res Ther 15(5):R102PubMedPubMedCentralCrossRef
43.
O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D (2009) Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 106:7113–7118PubMedPubMedCentralCrossRef
44.
O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104:1604–1609PubMedPubMedCentralCrossRef
45.
Thai T-H, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K (2007) Regulation of the germinal center response by microRNA-155. Science. 316:604–608PubMedCrossRef
46.
Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, Smith KGC, Rada C, Enright AJ, Toellner KM, MacLennan ICM, Turner M (2007) microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 27:847–859PubMedPubMedCentralCrossRef
47.
Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN (2008) MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 28:621–629PubMedPubMedCentralCrossRef
48.
Satoorian T, Li B, Tang X, Xiao J, Xing W, Shi W, Lau K-HW, Baylink DJ, Qin X (2016) MicroRNA223 promotes pathogenic T-cell development and autoimmune inflammation in central nervous system in mice. Immunology. 148:326–338PubMedPubMedCentralCrossRef
49.
Lind EF, Millar DG, Dissanayake D, Savage JC, Grimshaw NK, Kerr WG, Ohashi PS (2015) miR-155 upregulation in dendritic cells is sufficient to break tolerance in vivo by negatively regulating SHIP1. J Immunol 195(10):4632–4640PubMedCrossRef
50.
Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, Pierre P (2009) MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A 106(8):2735–2740PubMedPubMedCentralCrossRef
51.
Mann M, Barad O, Agami R, Geiger B, Hornstein E, Elaine Fuchs b miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate departments of a molecular genetics and
52.
Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y, Kawamura A, Nakamura K, Takeuchi T, Tanabe M (2007) An evolutionarily conserved mechanism for MicroRNA-223 expression revealed by microRNA gene profiling. Cell. 129:617–631PubMedCrossRef
53.
54.
Li YT, Chen SY, Wang CR, Liu MF, Lin CC, Jou IM, Shiau AL, Wu CL (2012) Amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223. Arthritis Rheum 64:3240–3245PubMedCrossRef
55.
Shibuya H, Nakasa T, Adachi N, Nagata Y, Ishikawa M, Deie M, Suzuki O, Ochi M (2013) Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation. Mod Rheumatol 23:674–685PubMedCrossRef
56.
Sugatani T, Hruska KA (2007) MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem 101:996–999PubMedCrossRef
57.
58.
Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, Chen H, Zhao LD, Zeng XF, Zhang FC, Tang FL, He W, Cao XT, Zhang X, Lipsky PE (2014) Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med 6(246):246ra99PubMedCrossRef
59.
Okkenhaug K, Burger JA (2016) PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Curr Top Microbiol Immunol 393:123–142PubMed
60.
Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y, Suda T (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202(3):345–351PubMedPubMedCentralCrossRef
61.
Maruyama K, Uematsu S, Kondo T, Takeuchi O, Martino MM, Kawasaki T, Akira S (2013) Strawberry notch homologue 2 regulates osteoclast fusion by enhancing the expression of DC-STAMP. J Exp Med 210(10):1947–1960PubMedPubMedCentralCrossRef
62.
Dou C, Zhang C, Kang F, Yang X, Jiang H, Bai Y, Xiang J, Xu J, Dong S (2014) MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim Biophys Acta 1839(11):1084–1096PubMedCrossRef
63.
McCubbrey AL, Nelson JD, Stolberg VR, Blakely PK, McCloskey L, Janssen WJ, Freeman CM, Curtis JL (2016) MicroRNA-34a negatively regulates efferocytosis by tissue macrophages in part via SIRT1. J Immunol 196(3):1366–1375PubMedCrossRef
64.
Xie H, Ye M, Feng R, Graf T (2004) Stepwise reprogramming of B cells into macrophages. Cell. 117(5):663–676PubMedCrossRef
65.
Rodriguez-Ubreva J, Ciudad L, van Oevelen C, Parra M, Graf T, Ballestar E (2014) C/EBPa-mediated activation of microRNAs 34a and 223 inhibits Lef1 expression to achieve efficient reprogramming into macrophages. Mol Cell Biol 34(6):1145–1157PubMedPubMedCentralCrossRef
66.
Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 512(7515):431–435PubMedCrossRef
67.
Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL (2011) MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 17(1):64–70PubMedCrossRef
68.
Lee Y, Kim HJ, Park CK, Kim YG, Lee HJ, Kim JY, Kim HH (2013) MicroRNA-124 regulates osteoclast differentiation. Bone. 56:383–389PubMedCrossRef
69.
Nakamachi Y, Ohnuma K, Uto K, Noguchi Y, Saegusa J, Kawano S (2016) MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats. Ann Rheum Dis 75(3):601–608PubMedCrossRef
70.
Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y (2013) Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24:542–556PubMedCrossRef
71.
Yang S, Zhang W, Cai M, Zhang Y, Jin F, Yan S, Baloch Z, Fang Z, Xue S, Tang R, Xiao J, Huang Q, Sun Y, Wang X (2018) Suppression of bone resorption by miR-141 in aged rhesus monkeys. J Bone Miner Res 33(10):1799–1812PubMedCrossRef
72.
Min S, Liang X, Zhang M, Zhang Y, Mei S, Liu J, Liu J, Su X, Cao S, Zhong X, Li Y, Sun J, Liu Q, Jiang X, Che Y, Yang R (2013) Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways. J Immunol 190(5):2437–2446PubMedCrossRef
73.
Chen C, Cheng P, Xie H, Zhou HD, Wu XP, Liao EY, Luo XH (2014) MiR-503 regulates osteoclastogenesis via targeting RANK. J Bone Miner Res 29(2):338–347PubMedCrossRef
74.
75.
Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, Takayanagi H (2011) Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 17(11):1473–1480PubMedCrossRef
76.
Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H (2012) Osteoprotection by semaphorin 3A. Nature. 485(7396):69–74PubMedCrossRef
77.
Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K (2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4(2):111–121PubMedCrossRef
78.
Takeshita S, Fumoto T, Matsuoka K, Park KA, Aburatani H, Kato S, Ito M, Ikeda K (2013) Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest 123(9):3914–3924PubMedPubMedCentralCrossRef
79.
Moverare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Borjesson AE, Sjogren K, Windahl SH, Farman H, Kindlund B et al (2014) Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat Med 20(11):1279–1288PubMedPubMedCentralCrossRef
80.
Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D (2016) Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30(6):836–848PubMedPubMedCentralCrossRef
81.
Li D, Liu J, Guo B, Liang C, Dang L, Lu C, He X, Cheung HY, Xu L, Lu C et al (2016) Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun 7(10872)
82.
Liang C, Guo B, Wu H, Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau WK, Cao Y, Yang Z, Lu C, He X, Au DWT, Pan X, Zhang BT, Lu C, Zhang H, Yue K, Qian A, Shang P, Xu J, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L, Lu A, Zhang G (2015) Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med 21(3):288–294PubMedPubMedCentralCrossRef
83.
Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G (2004) ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell. 117(3):387–398PubMedCrossRef
84.
Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A, Li D, Hou Z, Lv K, Kan G, Cao H, Wu H, Song J, Pan X, Sun Q, Ling S, Li Y, Zhu M, Zhang P, Peng S, Xie X, Tang T, Hong A, Bian Z, Bai Y, Lu A, Li Y, He F, Zhang G, Li Y (2013) miR-214 targets ATF4 to inhibit bone formation. Nat Med 19(1):93–100PubMedCrossRef
85.
Zhao C, Sun W, Zhang P, Ling S, Li Y, Zhao D, Peng J, Wang A, Li Q, Song J, Wang C, Xu X, Xu Z, Zhong G, Han B, Chang YZ, Li Y (2015) miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol 12(3):343–353PubMedPubMedCentralCrossRef
86.
Jindra PT, Bagley J, Godwin JG, Iacomini J (2010) Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J Immunol 185(2):990–997PubMedCrossRef
87.
Buckler JL, Walsh PT, Porrett PM, Choi Y, Turka LA (2006) Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J Immunol 177(7):4262–4266PubMedCrossRef
88.
Liu J, Li D, Dang L, Liang C, Guo B, Lu C, He X, Cheung HY, He B, Liu B et al (2017) Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Sci Rep 7(40487)
89.
Dambal S, Shah M, Mihelich B, Nonn L (2015) The microRNA-183 cluster: the family that plays together stays together. Nucleic Acids Res 43(15):7173–7188PubMedPubMedCentralCrossRef
90.
Ke K, Sul OJ, Rajasekaran M, Choi HS (2015) MicroRNA-183 increases osteoclastogenesis by repressing heme oxygenase-1. Bone. 81:237–246PubMedCrossRef
91.
Stittrich AB, Haftmann C, Sgouroudis E, Kuhl AA, Hegazy AN, Panse I, Riedel R, Flossdorf M, Dong J, Fuhrmann F et al (2010) The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol 11(11):1057–1062PubMedCrossRef
92.
Ichiyama K, Gonzalez-Martin A, Kim BS, Jin HY, Jin W, Xu W, Sabouri-Ghomi M, Xu S, Zheng P, Xiao C, Dong C (2016) The microRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression. Immunity. 44(6):1284–1298PubMedPubMedCentralCrossRef
93.
Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B (2018) Bone protection by inhibition of microRNA-182. Nat Commun 9(1):4108PubMedPubMedCentralCrossRef
94.
95.
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 147(2):358–369PubMedPubMedCentralCrossRef
96.
Mohammed MA, Syeda JTM, Wasan KM, Wasan EK (2017) An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 9(4)
Metadaten
Titel
Osteoclastic microRNAs and their translational potential in skeletal diseases
verfasst von
Kazuki Inoue
Shinichi Nakano
Baohong Zhao
Publikationsdatum
07.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Seminars in Immunopathology / Ausgabe 5/2019
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-019-00761-4

Weitere Artikel der Ausgabe 5/2019

Seminars in Immunopathology 5/2019 Zur Ausgabe

Review

Molecular determinants for the polarization of macrophage and osteoclast

Review

An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis

Introduction

Osteoimmunology: entwined regulation of integrated systems

Review

γδ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity

Review

Metabolic reprogramming in osteoclasts

Review

The role of bone cells in immune regulation during the course of infection

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise